The approval of Tibsovo was based on an open-label, single-arm, multicenter clinical trial (Study AG120-C-001) involving 174 patients with relapsed or refractory AML with an IDH1 miutation.
The researchers identified a combination of 10 autoantibody biomarkers that, as a panel, displayed a sensitivity, specificity, and an area under the curve of 79%, 84%, and 0.828, respectively, for primary melanoma detection.
In addition, Kisqali has also been approved in combination with fulvestrant to treat postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.
Infugem utilizes a novel technology that enables cytotoxic oncology products to be premixed in a sterile setting and to be supplied to prescribers in RTA infusion bags.
Researchers examined the risks of ovarian, breast, and corpus uteri cancer in 255,786 women who underwent assisted reproduction, with 2,257,789 person-years of follow-up.
When adjusting for age, body mass index, smoking status, calcium supplement intake, and study of origin, women with 25(OH)D concentrations ≥60ng/mL had an 80% lower risk of breast cancer than women with concentrations <20ng/mL (hazard ratio, 0.20; P=.03).
The approval was based on data from the ongoing Phase 2 CheckMate-142 study which enrolled patients with MSI-H/dMMR metastatic CRC who had received ≥1 prior line of therapy for metastatic disease (N=119).
The sBLA is based on results from the Phase 2 KEYNOTE-224 trial, which enrolled 104 individuals with advanced hepatocellular carcinoma previously treated with sorafenib who were either intolerant to or showed progression of disease after treatment.
Timely review and appropriate follow up on all patient reports is essential and must be part of a practice's routine.
The researchers found that 232 of the 499 participants randomized to MC1R testing logged on to the website, and of these, 88% (204 participants) requested testing and 82% (167 participants) returned the test kit.
The researchers found that women who underwent index screening mammography were more likely than unscreened women to later undergo Papanicolaou test (odds ratio, 1.49), bone mass measurement (odds ratio, 1.70), and influenza vaccine (odds ratio, 1.45).
The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Glasdegib, an investigational oral smoothened (SMO) inhibitor, is a once-daily therapy that is thought to work by disrupting the Hedgehog pathway.
The researchers found that a total of 219 of 933 patients (23%) in the enzalutamide group had metastasis or had died vs 228 of 468 (49%) in the placebo group.
The researchers found that for T1a diagnoses, participating pathologists' concordance with the consensus reference diagnosis increased from 44% with AJCC 7 criteria to 54% with AJCC 8 criteria.
The approval of these kinase inhibitors was supported by data from the Phase 3, randomized, active-controlled, open-label, multicenter COLUMBUS trial (N=577).
Current data suggest that people remain highly interested in being screened despite recognizing that a detected cancer may be indolent, which is partly due to fear of cancer.
PVSRIPO is a prototypic oncolytic recombinant polio virus vaccine that recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors.
The researchers found that the 5-year RCC-specific survival rate was 95 vs 98% after PA vs PN and 96 vs 95% after PA vs RN. The 5-year overall survival rate was 77 vs 86% after PA vs PN and 74 vs 75% after PA vs RN.
The sNDA is supported by data from the Phase 3 iNNOVATE (PCYC-1127) trial which assessed ibrutinib in combination with rituximab vs rituximab alone in 150 patients with previously untreated and relapsed/refractory WM.
Aspirin did not affect cancer incidence in men, women, or those aged ≥65 years in subgroup analyses but there was a decrease in cancer incidence associated with aspirin use among those aged <65 years.
The researchers found that 31% of survivors were not concerned about their future health and that 40% were not concerned about developing cancer.
Only 20% of the patients who died by suicide had a palliative care encounter, compared with 57% among lung cancer patients whose cause of death was not suicide.